CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive Gain (Loss)
Beginning Balance at Dec. 31, 2022	$ 490,151	$ 6	$ 878,884	$ (383,790)	$ (4,949)
Shares, Outstanding, Beginning Balance at Dec. 31, 2022		55,039,380
Exercise of stock options	1,486		1,486
Exercise of stock options, Shares		208,705
Vesting restricted stock, Shares		28,141
Stock-based compensation expense	9,385		9,385
Unrealized gain (loss) on marketable securities	1,911				1,911
Net loss	(40,928)			(40,928)
Ending Balance at Mar. 31, 2023	462,005	$ 6	889,755	(424,718)	(3,038)
Shares, Outstanding, Ending Balance at Mar. 31, 2023		55,276,226
Beginning Balance at Dec. 31, 2023	394,971	$ 6	926,269	(530,752)	(552)
Shares, Outstanding, Beginning Balance at Dec. 31, 2023		55,585,305
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs	301,373		301,373
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs, shares		3,884,158
Issuance of common stock through at-the market sales agreement, net of issuance costs		1,519,453
Issuance of common stock under ATM, net of issuance costs value	48,740		48,740
Exercise of stock options	3,933		3,933
Exercise of stock options, Shares		281,021
Vesting restricted stock, Shares		83,209
Stock-based compensation expense	11,968		11,968
Unrealized gain (loss) on marketable securities	(1,225)				(1,225)
Net loss	(48,557)			(48,557)
Ending Balance at Mar. 31, 2024	$ 711,203	$ 6	$ 1,292,283	$ (579,309)	$ (1,777)
Shares, Outstanding, Ending Balance at Mar. 31, 2024		61,353,146